Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 13 of 1,261
  1. US 12419873

    Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases

    ZHUHAI UNITED LABORATORIES CO., LTD. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  2. US 12419866

    Compounds and methods for treating an epileptic disorder

    The Regents of the University of California Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  3. US 12421193

    GPR52 modulators and methods of use

    Neurocrine Biosciences, Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  4. US 12419938

    Proenzyme composition

    Propanc Pty Ltd Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  5. US 12419877

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

    Akebia Therapeutics, Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  6. US 12419869

    Methods of treating multiple sclerosis

    VANDA PHARMACEUTICALS INC. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  7. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  8. US 12421249

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  9. US 2025290040

    GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE

    BEIGENE SWITZERLAND GMBH [CH] Β· Granted Sep 18, 2025 Β· Expires Sep 13, 2045

    granted
  10. US 12415867

    Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

    The Board of Regents of the University of Oklahoma Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  11. US 12415995

    Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders

    Northwestern University Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  12. US 12415845

    Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  13. US 12416006

    Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  14. US 12415856

    EGFR x CD28 multispecific antibodies

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  15. US 12415861

    Anti C-MET antibodies

    CENTESSA PHARMACEUTICALS (UK) LIMITED Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  16. US 12415779

    Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof

    NIKANG THERAPEUTICS, INC. Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  17. US 12415863

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  18. US 12415854

    Antibodies to TIGIT

    Arcus Biosciences, Inc. Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  19. US 12416008

    Compositions and methods of use for small-molecule regulation of CRISPR-Cas9 activity using RNA aptamers

    The Regents of the University of Colorado, a Body Corporate Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  20. US 12414999

    Compositions and methods relating to macrophages and/or monocytes with adhered particles

    The Regents of the University of California Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  21. US 12414983

    CD200AR ligands for cancer immunotherapy

    Regents of the University of Minnesota Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  22. US 12414995

    Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer

    Northwestern University Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  23. US 12414943

    Nimodipine parenteral administration

    Grace Therapeutics U.S., Inc. Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted
  24. US 12414953

    Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

    Prelude Therapeutics, Incorporated Β· Granted Sep 16, 2025 Β· Expires Sep 11, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.